SCHEMBL16123491

SCHEMBL16123491

COc1cc2c([nH]c3cc(O)ccc32)c(C)n1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DYRK1A Q13627 9/20 0.55
▸ KDM4E B2RXH2 5/20 0.45
▸ ALDH1A1 P00352 5/20 0.45
▸ HPGD P15428 5/20 0.45
▸ MAOA P21397 5/20 0.45
▸ HSD17B10 Q99714 4/20 0.45
▸ CYP3A4 P08684 2/20 0.45
▸ CYP2D6 P10635 2/20 0.45
▸ ACHE P22303 2/20 0.45
▸ CCNB2 O95067 2/20 0.45
▸ CDK1 P06493 2/20 0.45
▸ CCNB1 P14635 2/20 0.45
▸ CCNA2 P20248 2/20 0.45
▸ CDK2 P24941 2/20 0.45
▸ CCNA1 P78396 2/20 0.45
▸ CDK5 Q00535 2/20 0.45
▸ CDK5R1 Q15078 2/20 0.45
▸ CCNB3 Q8WWL7 2/20 0.45
▸ DYRK3 O43781 1/20 0.45
▸ CCNT1 O60563 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16103012 0.84 DYRK1A (0.76) DYRK1AKDM4EALDH1A1HPGDMAOA
SCHEMBL30939947 0.84 DYRK1A (0.76) DYRK1AKDM4EALDH1A1HPGDMAOA
SCHEMBL30939970 0.82 DYRK1A (0.49) DYRK1AKDM4EALDH1A1HPGDMAOA
SCHEMBL16123492 0.82 DYRK1A (0.49) DYRK1AKDM4EALDH1A1HPGDMAOA
SCHEMBL16123486 0.79 KDM4E (0.47) DYRK1AKDM4EALDH1A1HPGDMAOA
SCHEMBL647613 0.77 DYRK1A (0.55) DYRK1AKDM4EALDH1A1HPGDMAOA
SCHEMBL8852559 0.75 DYRK1A (0.53) DYRK1AKDM4EALDH1A1HPGDMAOA
SCHEMBL16102894 0.74 DYRK1A (0.74) DYRK1AKDM4EALDH1A1HPGDMAOA
SCHEMBL30939881 0.74 DYRK1A (0.74) DYRK1AKDM4EALDH1A1HPGDMAOA
SCHEMBL646288 0.73 DYRK1A (0.51) DYRK1AKDM4EALDH1A1HPGDMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3915987-B1 ALKYL-AMINE HARMINE DERIVATIVES FOR PROMOTING BONE GROWTH OSTEOQC INC (CA) 2023-12-13 — — EP disclosed
EP-3915987-A1 ALKYL-AMINE HARMINE DERIVATIVES FOR PROMOTING BONE GROWTH Osteoqc Inc. (CA) 2021-12-01 — — EP disclosed
EP-2968284-B1 ALKYL-AMINE HARMINE DERIVATIVES FOR PROMOTING BONE GROWTH OSTEOQC INC (CA) 2021-04-21 — — EP disclosed
US-20200172538-A1 COMPOUNDS FOR BONE GROWTH OSSIFI THERAPEUTICS LLC 2020-06-04 — — US disclosed
US-20170298059-A1 COMPOUNDS FOR BONE GROWTH OSSIFI THERAPEUTICS LLC 2017-10-19 — — US disclosed
US-20170298059-A1 COMPOUNDS FOR BONE GROWTH OSSIFI THERAPEUTICS LLC 2017-10-19 — — US disclosed
US-9540365-B2 Compounds for bone growth OSTEOQC INC. (CA) 2017-01-10 — — US disclosed
US-9540365-B2 Compounds for bone growth OSTEOQC INC. (CA) 2017-01-10 — — US disclosed
WO-2014153203-A2 ALKYL-AMINE HARMINE DERIVATIVES FOR PROMOTING BONE GROWTH OSSIFI INC. (US) 2014-09-25 — — WO disclosed
US-20140288068-A1 ALKYL-AMINE HARMINE DERIVATIVES FOR PROMOTING BONE GROWTH OSSIFI INC. (US) 2014-09-25 — — US disclosed
US-20140288068-A1 ALKYL-AMINE HARMINE DERIVATIVES FOR PROMOTING BONE GROWTH OSSIFI INC. (US) 2014-09-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200172538-A1 COMPOUNDS FOR BONE GROWTH FGF1, FGF2, BMP2 DYRK1A 4508/4885KDM4E 2795/4885ALDH1A1 655/4885
US-20170298059-A1 COMPOUNDS FOR BONE GROWTH FGF1, FGF2, BMP2 DYRK1A 4508/4885KDM4E 2795/4885ALDH1A1 655/4885
US-20140288068-A1 ALKYL-AMINE HARMINE DERIVATIVES FOR PROMOTING BONE GROWTH TPH1, TPH2, HTR5A DYRK1A 3234/4885KDM4E 701/4885ALDH1A1 702/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback